TC Biopharm, Scotia Biologics in immuno-oncology deal

TC BioPharm Ltd. (Edinburgh, U.K.) and Scotia Biologics (Aberdeen, U.K.) partnered to co-develop CAR T cell therapies using tumor-specific antibodies.

CBO Artin Moussavi told BioCentury that TC BioPharm gains exclusive, worldwide rights to tumor-specific single-chain antibodies generated under the deal. TC BioPharm will use its ImmuniCAR platform to develop the antibodies into CAR T-based immunotherapies...